Sutro Biopharma (STRO) Other Operating Expenses (2025)

Sutro Biopharma (STRO) reported Other Operating Expenses of $2.8 million for Q4 2025, up 25.02% sequentially from $2.2 million in Q3 2025.

Sutro Biopharma (STRO) Other Operating Expenses (2025) Analysis & Trends

Sutro Biopharma (STRO) has 1 years of Other Operating Expenses data on file, last reported at $2.8 million in Q4 2025.

For the quarter ending Q4 2025, Other Operating Expenses changed N/A year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2025 stood at $27.3 million (changed N/A YoY), and the FY2025 full-year result was -$9.8 million, changed N/A from the prior year.
Other Operating Expenses improved to $2.8 million in Q4 2025, from $2.2 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $16.8 million in Q1 2025 to a low of $2.2 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Sutro Biopharma	192.86 Mn	51.43 Mn	-

Download Data